[引用][C] Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
ME Balcells Marty, LE Rojas Orellana… - 2021
[PDF][PDF] COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review. 2
Interventions–Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration 111
http://www. cochranehandbook. org.]. The Cochrane'Risk of bias' tool for RCTs addresses …
http://www. cochranehandbook. org.]. The Cochrane'Risk of bias' tool for RCTs addresses …
Erratum: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study …
CM Eckhardt, MJ Cummings… - …, 2020 - utsouthwestern.elsevierpure.com
Following publication of the original article [1], the authors identified an error in the author
name of Andrew Eisenberger. The incorrect author name is: Andrew Eisenberg The correct …
name of Andrew Eisenberger. The incorrect author name is: Andrew Eisenberg The correct …
Uso de plasma convalescente no tratamento da COVID-19: protocolo de revisão sistemática
MR Santos, CRL Silva - Online braz. j. nurs.(Online), 2022 - pesquisa.bvsalud.org
OBJETIVO: analisar a efetividade terapêutica do plasma convalescente utilizado em
pacientes com confirmação de diagnóstico de COVID-19. MÉTODO: revisão sistemática …
pacientes com confirmação de diagnóstico de COVID-19. MÉTODO: revisão sistemática …
[HTML][HTML] A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID-19 Patients
H Al Hashmi, D Alawami, SZA Zaidi, NF Alshehry… - Blood, 2020 - Elsevier
Introduction Coronavirus disease (COVID-19) pandemic has started to affect Saudi Arabia in
the beginning of March 2020 and is expected to cause significant morbidity to many patients …
the beginning of March 2020 and is expected to cause significant morbidity to many patients …
Early outpatient treatment for Covid-19 with convalescent plasma
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …
[HTML][HTML] Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study …
CM Eckhardt, MJ Cummings, KN Rajagopalan… - Trials, 2020 - Springer
Objectives The aim of this study is to evaluate the efficacy and safety of human anti-SARS-
CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. Trial …
CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection. Trial …
[HTML][HTML] Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control
P Cacilhas, E Caberlon, L Angoleri… - Brazilian Journal of …, 2022 - SciELO Brasil
Convalescent plasma therapy has shown controversial results in coronavirus disease-19
(COVID-19) patients. We performed a non-randomized case-control study with …
(COVID-19) patients. We performed a non-randomized case-control study with …
[HTML][HTML] Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
K Holm, MN Lundgren, J Kjeldsen-Kragh… - BMC Research …, 2021 - Springer
Objective Convalescent plasma has been tried as therapy for various viral infections. Early
observational studies of convalescent plasma treatment for hospitalized COVID-19 patients …
observational studies of convalescent plasma treatment for hospitalized COVID-19 patients …
[PDF][PDF] Is convalescent plasma futile in COVID-19
abstract Background: Randomized trials are generally performed from a frequentist
perspective, which can conflate absence of evidence with evidence of absence. The …
perspective, which can conflate absence of evidence with evidence of absence. The …